Generation Bio Co. (NASDAQ:GBIO) Stock Holdings Decreased by Jane Street Group LLC

Jane Street Group LLC lowered its position in shares of Generation Bio Co. (NASDAQ:GBIO) by 29.9% during the third quarter, Holdings Channel reports. The fund owned 34,783 shares of the company’s stock after selling 14,835 shares during the quarter. Jane Street Group LLC’s holdings in Generation Bio were worth $86,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. FMR LLC grew its position in Generation Bio by 0.3% during the 3rd quarter. FMR LLC now owns 5,320,266 shares of the company’s stock worth $13,141,000 after purchasing an additional 15,656 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in shares of Generation Bio by 61.1% during the third quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock valued at $4,804,000 after buying an additional 737,988 shares in the last quarter. State Street Corp raised its position in Generation Bio by 1.2% during the third quarter. State Street Corp now owns 992,188 shares of the company’s stock valued at $2,451,000 after buying an additional 11,669 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Generation Bio by 2.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock worth $1,046,000 after acquiring an additional 8,692 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Generation Bio by 31.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company’s stock worth $527,000 after acquiring an additional 44,378 shares during the period. Hedge funds and other institutional investors own 95.22% of the company’s stock.

Insiders Place Their Bets

In other Generation Bio news, Director Anthony G. Quinn acquired 125,791 shares of Generation Bio stock in a transaction that occurred on Friday, January 10th. The stock was acquired at an average price of $0.96 per share, with a total value of $120,759.36. Following the purchase, the director now owns 214,286 shares in the company, valued at approximately $205,714.56. This trade represents a 142.14 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 21.10% of the company’s stock.

Analysts Set New Price Targets

GBIO has been the topic of a number of research reports. Needham & Company LLC dropped their target price on Generation Bio from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Wedbush reiterated an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a research report on Thursday, November 7th.

Generation Bio Trading Down 4.3 %

Shares of NASDAQ:GBIO opened at $0.88 on Wednesday. The business has a fifty day simple moving average of $1.35 and a 200 day simple moving average of $2.13. Generation Bio Co. has a 1 year low of $0.75 and a 1 year high of $4.65. The firm has a market cap of $58.78 million, a price-to-earnings ratio of -0.40 and a beta of 2.72.

Generation Bio Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.